http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020007898-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a60649a09a47690f2c5082c03fbc2212 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c7d4d0cdc9f5df2ad6a9e21f7ad7611 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c930c1a3fcc9a93dc304ab4a77bd0ea3 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 |
| filingDate | 2019-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d1cd70950b7de4deb982ac404922d5d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9e282e17fd241ad332f14b4f14f5216 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ab0f7ba063bdae9e96f8a5be84e7543 |
| publicationDate | 2020-01-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2020007898-A1 |
| titleOfInvention | Methods and compositions for treating brain injury or neurodegenerative disease |
| abstract | The present invention relates to a method for treating brain injury or neurodegenerative disease in a subject in need thereof comprising a step of administering said subject with a therapeutically effective amount of a syndecan-1 agonist. Inventors have shown a different expression pattern of Syndecan-1 between quiescent and activated neural stem cells (NSCs) and demonstrated its role in the proliferation of activated NSCs. They have shown that syndeacan-1 is a marker of proliferative NSCs. Their data highlight the central role of the stem cell microenvironment in the regulation of quiescence in adult neurogenic niches. Finally, inventors unravel the role of Syndecan-1 (Sdc1) in the proliferation of activated NSCs. Interestingly, Sdc1 transcripts, highly enriched in proliferative cells, significantly decreased after BMP4 treatment. To confirm the role of SDC1 in the proliferation of activated NSCs, they performed silencing experiments using siRNA directed against Sdc1. Accordingly, inventors have found new approaches for NSC-based regenerative medicine. |
| priorityDate | 2018-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 733.